Volume 74, Issue 4, Pages (October 2018)

Slides:

Advertisements

Similar presentations

The PSA Era is not Over for Prostate Cancer

Advertisements

Volume 50, Issue 1, Pages (July 2006)

Volume 51, Issue 2, Pages (February 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 2, Pages (August 2010)

Volume 58, Issue 4, Pages (October 2010)

Testosterone Therapy in Men With Prostate Cancer

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 60, Issue 2, Pages (August 2011)

Volume 46, Issue 3, Pages (September 2004)

Volume 53, Issue 5, Pages (May 2008)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 51, Issue 4, Pages (April 2007)

Let the Games Begin (with EAU Approval)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 63, Issue 1, Pages (January 2013)

Volume 53, Issue 2, Pages (February 2008)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 54, Issue 4, Pages (October 2008)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 61, Issue 4, Pages (April 2012)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 54, Issue 5, Pages (November 2008)

Volume 66, Issue 3, Pages (September 2014)

Volume 59, Issue 4, Pages (April 2011)

Volume 67, Issue 6, Pages (June 2015)

Volume 64, Issue 6, Pages (December 2013)

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 2, Pages (February 2008)

Volume 64, Issue 4, Pages (October 2013)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Volume 53, Issue 6, Pages (June 2008)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 74, Issue 2, Pages (August 2018)

Volume 68, Issue 4, Pages (October 2015)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography Andrew.

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients Macarena R.

Volume 71, Issue 5, Pages (May 2017)

Volume 66, Issue 6, Pages (December 2014)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 70, Issue 1, Pages (July 2016)

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Follow up results of a prospective study to evaluate the impact of FDG-PET on CT- based radiotherapy treatment planning for oesophageal cancer Sweet Ping.

European Urology is “Your” Journal

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Volume 53, Issue 6, Pages (June 2008)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Volume 51, Issue 2, Pages (February 2007)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 74, Issue 4, Pages 455-462 (October 2018) Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial Shankar Siva, Mathias Bressel, Declan G. Murphy, Mark Shaw, Sarat Chander, John Violet, Keen Hun Tai, Cristian Udovicich, Andrew Lim, Lisa Selbie, Michael S. Hofman, Tomas Kron, Daniel Moon, Jeremy Goad, Nathan Lawrentschuk, Farshad Foroudi European Urology Volume 74, Issue 4, Pages 455-462 (October 2018) DOI: 10.1016/j.eururo.2018.06.004 Copyright © 2018 Terms and Conditions

Fig. 1 Survival. (A) Local progression-free survival and (B) distant progression-free survival. European Urology 2018 74, 455-462DOI: (10.1016/j.eururo.2018.06.004) Copyright © 2018 Terms and Conditions

Fig. 2 Waterfall plot of maximal change in prostate-specific antigen (PSA) from baseline characterized by lesion type. European Urology 2018 74, 455-462DOI: (10.1016/j.eururo.2018.06.004) Copyright © 2018 Terms and Conditions

Fig. 3 Patterns of failure based on disease location of oligometastases (nodal only versus bone only). One patient was excluded from this chart due to extra pelvic nodal disease only, and one further patient with mixed bone and nodal disease. European Urology 2018 74, 455-462DOI: (10.1016/j.eururo.2018.06.004) Copyright © 2018 Terms and Conditions